Rajni Natesan, MD, MBA, Spearheads Precision Oncology Efforts in Real-World Settings

Clinical trials can demonstrate a drug’s efficacy and safety. Biomarker tests can match the right drug with the right patient. FDA can give its approval, and the National Comprehensive Cancer Network (NCCN) can add a new therapy to its guidelines.

Clarified Precision Medicine’s Mission: Bridging the Gap in Precision Oncology

What CEO Rajni Natesan, MD, MBA, calls the “last mile,” is what her company is built to tackle: erasing the gaps that occur when the promise of precision oncology meets the reality of a busy clinic. Although biomarker testing has shown improvement in certain cancers and has been deemed cost-effective, a report in JCO Clinical Practice pointed out pain points that hindered patients from benefiting from precision oncology.

Revolutionizing Precision Oncology through Artificial Intelligence

Clarified Precision Medicine harnesses the power of artificial intelligence (AI) to streamline the process of analyzing next-generation sequencing (NGS) results from multiple laboratory tests. This innovative approach saves time for oncologists inundated with patients, allowing them to focus on treatment decisions rather than getting lost in complicated reports.

Human-Centric Approach: Marrying Technology with Expertise

CEO Rajni Natesan emphasizes the crucial role of human reviewers in the process, ensuring that the AI algorithm’s recommendations align with evidence-based guidelines. This fusion of cutting-edge technology and human expertise sets Clarified apart in the field of precision oncology.

Real-World Impact and Future Directions

Clarified Precision Medicine’s products, Clarified Select and OncoGuardian, offer guideline-based recommendations to providers, simplifying complex genomic test results into actionable insights. The company’s success in pilot programs and collaborations with healthcare systems demonstrates the growing acceptance and value of precision oncology services.

Empowering Patients and Providers: The Future of Precision Medicine

By bridging the gap between genomic testing and clinical decision-making, Clarified Precision Medicine aims to revolutionize the delivery of precision oncology in real-world settings. With a focus on enhancing patient outcomes, reducing costs, and providing personalized care, the company is paving the way for a new era in cancer treatment.

Conclusion

Clarified Precision Medicine’s innovative approach to precision oncology showcases the transformative potential of AI in improving patient outcomes and streamlining clinical workflows. By addressing the challenges faced by oncologists in interpreting complex genomic reports, Clarified is poised to revolutionize the field of precision medicine, offering hope and personalized care to patients in need.

IntelliPrompt curated this article: Read the full story at the original source by clicking here